All News

Regulatory & Standards

NICE Approves CAR-T as NHS Treatment for Aggressive Forms of Blood Cancer
1 February 2023
NICE Approves CAR-T as NHS Treatment for Aggressive Forms of Blood Cancer
NICE has announced the approval
Allogeneic Therapies: Can This be the Silver Bullet for All Future Cell Therapy Developers?
25 January 2023
Allogeneic Therapies: Can This be the Silver Bullet for All Future Cell Therapy Developers?
In this guest column, Renu
Top 10 Events in Cell & Gene Therapy 2022
18 January 2023
Top 10 Events in Cell & Gene Therapy 2022
It’s day 1 of Advanced
Lessons in Commercial Success
4 January 2023
Lessons in Commercial Success
For this interview, Phacilitate’s Becky-Johnson
POPULAR NEWS ITEMS
Image
3 February 2023

Navigating the Applications of Title21’s Manufacturing Execution System

Image
2 February 2023

ScaleReady Demonstrate Cue – A Platform for Small Volume Cell Processing

Image
1 February 2023

NICE Approves CAR-T as NHS Treatment for Aggressive Forms of Blood Cancer

5 Things to Consider when Sourcing Plasmids
15 December 2022
5 Things to Consider when Sourcing Plasmids
Dr Katie Roberts presents 5
A Novel Technology for AAV Manufacture: TESSA™ in the Spotlight
15 December 2022
A Novel Technology for AAV Manufacture: TESSA™ in the Spotlight
Over the past year or
The Clinical Landscape of Gene Therapies in 2022
15 December 2022
The Clinical Landscape of Gene Therapies in 2022
Phacilitate’s Georgi Makin and Anna
EMA Accepts Application for Breakthrough Treatment of Genetic Form of ALS
5 December 2022
EMA Accepts Application for Breakthrough Treatment of Genetic Form of ALS
Biogen, has announced the European
Load more News
RECOMENDED TOPICS
Clinical Trials
Collaborations, Mergers & Acquisitions
Finance & Investment
Patient Access & Engagement
Regulatory & Standards
Reimbursement
Strategy
POPULAR NEWS ITEMS
Image

Navigating the Applications of Title21’s Manufacturing Execution System

Image

ScaleReady Demonstrate Cue – A Platform for Small Volume Cell Processing

Image

NICE Approves CAR-T as NHS Treatment for Aggressive Forms of Blood Cancer